A Double-blind, Randomized, Parallel Group, Phase IV Study to Investigate the Effects of DAPAgliflozin on CARDiac Substrate Uptake, Myocardial Efficiency and Myocardial Contractile Work in Type 2 Diabetes Patients
Latest Information Update: 02 Nov 2023
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DAPACARD
- Sponsors AstraZeneca
- 06 Oct 2023 Results assessing the effects of dapagliflozin on tissue fatty acid metabolism in subjects with type 2 diabetes (T2D) by using positron emission tomography presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 17 Oct 2021 Results of an analysis of a mechanistic mathematical model of cardiorenal physiology was used to quantify the influence of established natriuretic/diuretic effects of SGLT2i on cardiac function (myocardial efficiency and global longitudinal strainpublished in the Journal of Clinical Pharmacology
- 01 Jul 2021 Primary endpoint (Global longitudinal strain of the left ventricle (GLSLV)) has not been met.